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Herpesviruses can rewire cellular signaling in host cells
by expressing viral G protein– coupled receptors (GPCRs).
These viral receptors exhibit homology to human chemokine
receptors, but some display constitutive activity and promis-
cuous G protein coupling. Human cytomegalovirus (HCMV)
has been detected in multiple cancers, including glioblas-
toma, and its genome encodes four GPCRs. One of these
receptors, US28, is expressed in glioblastoma and possesses
constitutive activity and oncomodulatory properties. UL33,
another HCMV-encoded GPCR, also displays constitutive
signaling via Gq, Gi, and Gs proteins. However, little is
known about the nature and functional effects of UL33-
driven signaling. Here, we assessed UL33’s signaling reper-
toire and oncomodulatory potential. UL33 activated multiple
proliferative, angiogenic, and inflammatory signaling path-
ways in HEK293T and U251 glioblastoma cells. Notably, upon
infection, UL33 contributed to HCMV-mediated STAT3 activa-
tion. Moreover, UL33 increased spheroid growth in vitro and
accelerated tumor growth in different in vivo tumor models,
including an orthotopic glioblastoma xenograft model. UL33-
mediated signaling was similar to that stimulated by US28;
however, UL33-induced tumor growth was delayed. Addi-
tionally, the spatiotemporal expression of the two receptors
only partially overlapped in HCMV-infected glioblastoma
cells. In conclusion, our results unveil that UL33 has broad
signaling capacity and provide mechanistic insight into its
functional effects. UL33, like US28, exhibits oncomodulatory
properties, elicited via constitutive activation of multiple
signaling pathways. UL33 and US28 might contribute to
HCMV’s oncomodulatory effects through complementing
and converging cellular signaling, and hence UL33 may
represent a promising drug target in HCMV-associated
malignancies.
Human cytomegalovirus (HCMV),2 Epstein–Barr virus
(EBV), and Kaposi’s sarcoma–associated herpesvirus (KSHV)
are members of Herpesviridae linked to oncogenesis. EBV and
KSHV are oncogenic viruses (1, 2), whereas HCMV is consid-
ered an oncomodulatory virus that aggravates rather than ini-
tiates tumorigenesis (3). Each of the viruses contain genes
encoding for one or more G protein– coupled receptors
(GPCRs) showing homology to human chemokine receptors
(4). Several viral GPCRs, i.e. HCMV-encoded US28 (5, 6), EBV-
encoded BILF1 (7), and KSHV-encoded ORF74 (8), possess
oncogenic or oncomodulatory properties. These viral receptors
are constitutively active and show G protein promiscuity,
whereas human chemokine receptors are only activated upon
agonist stimulation and predominantly couple to Gi proteins.
By means of this constitutive GPCR signaling, herpesviruses
have devised mechanisms to rewire cellular signaling of host
cells to facilitate virus biology and consequent pathogenesis.
HCMV is a ubiquitous DNA virus with a seroprevalence of
more than 50% in adults (9). Once acquired, this -herpesvirus
establishes a life-long latent infection, which is usually asymp-
tomatic. However, under conditions in which the immune sys-
tem is compromised (e.g. in AIDS patients or organ transplan-
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tation recipients or upon tumor-associated inflammation),
reactivation of HCMV may result in severe pathologies (10).
HCMV DNA and proteins have been detected in tumor sam-
ples of multiple human cancers (11–17) in which the virus
exerts oncomodulatory properties (3, 15, 18–20). HCMV
encodes four GPCRs: UL33, UL78, US27, and US28 (21). These
receptors are present on the virion (22–26), and transcripts of
each have been detected in peripheral blood mononuclear cells
obtained from asymptomatic latently infected individuals (27).
Ligands for UL33, UL78, and US27 have not been identified to
date. US28, in contrast, binds to and internalizes a large number
of human chemokines (e.g. CX3CL1 and CCL2–5, -7, -11, -13,
-26, and -29), contributing to HCMV-mediated immune eva-
sion (4, 28). At present, only UL33 and US28 have been shown
to couple to G proteins and display G protein– dependent sig-
naling (4, 29, 30).
US28 promiscuously couples to Gs, Gi, Gq, and G12/13
proteins and constitutively activates downstream signaling,
including proinflammatory, proangiogenic, and proliferative
pathways (5, 31, 32). Additionally, US28 can modulate migra-
tion of macrophages and smooth-muscle cells in a ligand-de-
pendent manner (33) and is essential for establishment of latent
infection in hematopoietic progenitor cells and monocytes
(34, 35). In vitro and in vivo studies have also demonstrated
an oncomodulatory role for US28. For example, tumor for-
mation was induced upon expression of US28 in xenograft
models and transgenic mice (5, 6, 36), and US28 expression
in glioblastoma cells accelerated tumor growth in an ortho-
topic mice model (20). Importantly, US28 expression is
detected in brain tumor specimens obtained from HCMV-
positive glioblastoma patients (16, 20, 31).
UL33 also signals in a constitutive manner. Expression of this
viral GPCR results in production of inositol phosphate (InsP)
and activation of CREB via coupling to Gq/Gi and Gs pro-
teins, respectively (29, 30). Furthermore, significant contribu-
tion of UL33 to HCMV-mediated CREB activation was demon-
strated in HCMV-infected glioblastoma cells (30). Experiments
using R33 and M33, UL33 homologs expressed by rodent-spe-
cific cytomegaloviruses, have illustrated pathological relevance
of UL33 gene family members. Deletion of R33 from rat cyto-
megalovirus (RCMV) highlighted the contribution of R33 to
virus replication in vivo. Moreover, lower mortality rates were
observed in rats infected with R33-knockout virus (37). Consti-
tutive G protein– dependent signaling by murine cytomegalo-
virus (MCMV) M33 was shown to promote migration of
infected lung dendritic cells, which is required for entrance to
the blood circulation and systemic spread of the virus (38).
Accordingly, deletion of M33 from MCMV hampered virus
replication in the salivary gland and spleen (39, 40). Establish-
ing, maintaining, or reactivation from latency in the spleen and
lungs was strongly dependent on constitutive signaling by M33
(40, 41). Interestingly, complementation with either UL33 or
US28 partially rescued the attenuation of viral replication and
establishment of latent infection upon deletion of M33 from
MCMV, indicating conserved functionality between UL33 and
M33 as well as functional overlap between UL33 and US28
(39, 40).
Although UL33 displays promiscuous G protein coupling
and constitutive activity, limited information is available on the
signaling properties and functional consequences of UL33. In
this study, we explored the signaling repertoire of UL33 as well
as its contribution to oncomodulation. Our data demonstrate
that UL33 is capable of enhancing tumor growth via constitu-
tive activation of proinflammatory, proliferative, and proangio-
genic signal transduction pathways. Hence, UL33 could play an
important role in the pathogenesis of HCMV-associated
malignancies.
Results
UL33 constitutively activates oncogenic signaling pathways
UL33 promiscuously couples to G proteins in a constitutive
manner (30). We evaluated the ability of UL33 to activate
inflammatory and oncogenic signaling pathways using lucifer-
Figure 1. UL33 and US28 mediate constitutive activation of proliferative and proangiogenic signal transduction pathways in HEK293T cells. A,
dose-dependent receptor expression in HEK293T cells transiently transfected with increasing amounts of DNA encoding UL33-HA or US28-HA (C-terminally
epitope-tagged receptors), as assessed through anti-HA ELISA. B, HEK293T cells were transfected with 12 ng of UL33-HA or 40 ng of US28-HA/106 cells in
combination with the corresponding luciferase reporter genes. At similar expression levels, the constitutive activation of multiple signaling pathways was
assessed. Mock cells (transfected with reporter gene plasmid) were stimulated with 8 pM TGF for 24 h as a positive control for SMAD3 activation. Constitutive
NF-B activation (C) or InsP production (D) was assessed in HEK293T cells transfected with a series of DNA encoding UL33-HA or US28-HA. AlF3 was included
as positive control in the InsP production assay. Graphs are representatives of at least three individual experiments performed in triplicate, and data are
presented as mean  S.D. (error bars). *, p  0.05; **, p  0.01; and ****, p  0.0001.
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ase-based reporter genes and compared it with US28-media-
ted signaling. Upon transfection of UL33 or US28 DNA in
HEK293T cells, dose-dependent receptor expression was
observed (Fig. 1A). To compare the intrinsic signaling capacity
of UL33 and US28, signaling was evaluated at equal total pro-
tein levels of the receptors (Fig. S1A). UL33 constitutively
induced activation of STAT3, AP-1, NFAT, TCF/LEF, HIF-1,
the VEGF promoter, and the COX-2 promoter to a degree com-
parable with that of US28 (Fig. 1B). The SMAD3 reporter was
refractory to input by both UL33 and US28, whereas TGF
stimulation, serving as a positive control, resulted in a pro-
nounced activation of this transcriptional readout. Interest-
ingly, CREB, NF-B, and SRF were differentially activated by
the two GPCRs (Fig. 1B). UL33 enhanced CREB activity 120-
fold, compared with 65-fold for US28. In contrast, activation of
NF-B and SRF was less pronounced for UL33 compared with
US28 (2- versus 12-fold for NF-B and 12- versus 21-fold for
SRF). At higher expression levels, UL33-mediated NF-B acti-
vation reached a maximum at 2.7-fold, compared with 10-fold
for US28 (Fig. 1C). For comparison, a similar range of UL33
expression resulted in a dose-dependent UL33-driven COX-2
promoter activation (Fig. S1B). Previously, UL33 was reported
to increase InsP production in COS-7 cells via coupling to
Gq/11 and Gi proteins (29, 30). In HEK293T cells, UL33 stim-
ulated InsP production only at the highest DNA dose used (1.7-
fold), whereas US28 enhanced InsP levels in a dose-dependent
fashion (up to 8-fold) (Fig. 1D). Together, these data indicate
that UL33 constitutively activates multiple proliferative, angio-
genic, and proinflammatory signaling pathways, which partially
overlap with US28-mediated signaling despite some distinct
differences.
UL33 stimulates transformation of NIH-3T3 cells
To evaluate oncomodulatory properties of UL33, a stable
NIH-3T3 cell line expressing UL33-eGFP was generated (Fig.
S2). Like expression of US28, but to a lesser extent, UL33
expression resulted in loss of contact inhibition in NIH-3T3
cells as evidenced by the formation of foci (Fig. 2A). Inhibition
of Gq-mediated signaling using YM-254890 abolished foci
formation induced by both receptors. Because UL33 activated
proliferative and proangiogenic signaling pathways and in-
duced a transformed phenotype in vitro, UL33’s potential to
induce tumor formation in vivo was assessed. Tumors were
observed 13 days after subcutaneous inoculation of UL33- or
US28-expressing NIH-3T3 cells in both flanks of athymic nude
mice (Fig. 2B). The mock-treated group did not develop tumors
up to 75 days postinjection. Although the oncostimulatory
potential of US28 was more pronounced, UL33 clearly induced
tumor formation in vivo. These findings demonstrate that
UL33, like US28, induces cellular transformation.
UL33 signaling in glioblastoma cells
To probe the properties of the viral GPCRs in a disease-rel-
evant cellular background, we generated U251 glioblastoma
cell lines with inducible receptor expression (U251 iUL33,
U251 iUL33-HA, U251 iUS28, and U251 iHA-US28). Upon
induction of receptor expression using doxycycline, UL33 and
US28 were expressed at similar levels (Fig. S3). Subsequently,
UL33-mediated signaling was assessed in these glioblastoma
cells. InsP levels were not increased by UL33 expression,
whereas US28-expressing cells exhibited a 25-fold increase in
InsP production (Fig. 3A). Both receptors induced activation of
TCF/LEF, albeit to a different extent (17.5-fold for UL33 versus
2.7-fold for US28) (Fig. 3B). Additionally, expression of either
UL33 or US28 resulted in a pronounced increase in STAT3
Tyr705 phosphorylation and IL-6 secretion (Fig. 3, C and D).
US28 expression resulted in more STAT3 activation compared
with UL33, whereas the receptors induced the secretion of IL-6
by a similar grade. Thus, UL33 also activates oncomodulatory
signaling in U251 glioblastoma cells.
UL33 contributes to HCMV-mediated STAT3 activation in
glioblastoma cells
Next, we set out to study UL33 and US28 in the context of
HCMV-infected U251 cells. To facilitate our studies, we genet-
ically engineered the bacterial artificial chromosome (BAC) of
the clinically relevant HCMV Merlin strain (pAL1502 (42)).
Introduction of an HA epitope at the C terminus of UL33
allowed for simultaneous detection of UL33 and US28 protein
expression. UL33- or US28-knockout viruses were generated to
Figure 2. UL33 induces an oncogenic phenotype in NIH-3T3 cells. A, the formation of foci by NIH-3T3 cells stably transfected with empty vector (Mock),
UL33-eGFP, or US28 treated with vehicle (0.03% DMSO) or 300 nM YM-254890. B, tumor formation in nude mice flank-inoculated with NIH-3T3 cells stably
expressing UL33-eGFP or US28 (six mice per cell line, inoculated in both flanks). Data are depicted as mean  S.E. (error bars). *, p  0.05; **, p  0.01; and ****,
p  0.0001.
Oncomodulatory activity of HCMV-encoded GPCR UL33























evaluate the contribution of the respective receptors to HCMV-
mediated effects. Integrity of the BACs was confirmed via endo-
nuclease restriction profile analysis as well as sequencing of the
UL33 and US28 gene regions, respectively (Fig. S4A).
Upon infection with Merlin UL33-HA virus, UL33-HA and
US28 protein expression was monitored each day postinfection
(dpi) for a period of 9 consecutive days (Fig. 4A). HCMV imme-
diate-early 1 (IE1) protein was detected in the nucleus of
infected cells throughout the time frame of analysis. UL33
expression was apparent at 4 –9 dpi, whereas low levels of US28
were already observed at 2 dpi, and intense US28 staining was
evident from 3 to 9 dpi.
The expression pattern of UL33 and US28 was variable
between infected cells with some cells expressing high levels of
both receptors, whereas in other cells the staining was less pro-
found (Fig. 4B). Despite synchronized infection, part of the cells
expressed one receptor more than the other, indicating that
UL33 and US28 expression might be controlled by distinct reg-
ulatory mechanisms of the host cell. Previous research by
Fraile-Ramos et al. (43, 44) revealed the presence of UL33 and
US28 in the virion assembly compartment (VAC) of HCMV-
infected fibroblasts. Although only a subset of infected U251
cells display a typical circular and perinuclear VAC, as identi-
fied by the viral tegument protein pp28 (45), both receptors
colocalized in the VAC (Fig. 4C). Compared with the apparent
strict perinuclear localization of US28 in cells where a VAC was
present, UL33 protein was also more dispersed throughout the
cell (Fig. 4D). In conclusion, US28 and UL33 are expressed
upon HCMV infection of U251 glioblastoma cells but with dis-
tinct expression kinetics and subcellular localization.
Employing U251 cells stably expressing a reporter gene
(U251–3SFP), STAT3-mediated signaling of UL33 and US28 in
HCMV-infected glioblastoma cells was examined. HCMV
Merlin infection strongly enhanced STAT3 activity 5 dpi when
both receptors were expressed in U251 cells (9-fold) (Fig. 4E).
At a similar infection rate (Fig. S4B), STAT3 activation was
significantly impaired in cells infected with either UL33- or
US28-knockout virus (57 and 47% reduction, respectively) (Fig.
4F). Parallel infection of U251–3SFP and U251 cells constitu-
tively expressing firefly luciferase/mCherry (U251-FM) showed
that the rise in STAT3 activity was not due to a general increase
in transcriptional activity in HCMV-infected U251 cells (Fig.
S4C). These results indicate that UL33, like US28, activates pro-
liferative signaling in HCMV-infected U251 cells.
UL33 aggravates glioblastoma tumor growth
Finally, we determined the effect of UL33 on proliferation of
glioblastoma cells. Expression of UL33 or US28 in U251 cells
enhanced 3D growth, resulting in a 1.7- and 2.2-fold increase in
spheroid size, respectively (Fig. 5A). An orthotopic glioblas-
toma mouse model was established to study the contribution of
UL33 in glioblastoma progression in situ. To this end, U251,
U251 iUL33, and U251 iUS28 cells constitutively expressing
firefly luciferase/mCherry (FM) were constructed to quantify
tumor size using bioluminescence imaging (20, 46). Following
inoculation of these cells in the striatum of nude athymic mice,
expression of UL33 or US28 induced tumor growth (Fig. 5B).
No tumor development was observed in mice inoculated with
U251-FM control cells within the time frame of the experiment
(50 days). The onset of UL33-mediated tumor growth was
delayed compared with tumor formation by US28-expressing
cells (32 versus 14 days postinjection). A similar pattern was
apparent for the mortality of the mice (Fig. 5C). This delayed
onset of tumor growth for UL33-expressing cell lines could be
attributed to lower receptor expression levels. Evaluation of
receptor mRNA levels in the cells used for inoculation of the
mice showed higher abundance of UL33 than US28 mRNA (Fig.
S5), suggesting that differential signaling properties, not recep-
tor expression levels, account for the delayed onset of UL33-
mediated tumor growth. Taken together, these observations
illustrate that UL33 can aggravate glioblastoma tumor growth,
albeit to a lesser extent than US28.
Discussion
A growing body of evidence has substantiated the concept of
oncomodulation by HCMV in the context of glioblastoma (18).
Figure 3. UL33 signaling in U251 malignant glioma cells. The effects of UL33 and US28 expression on InsP production (A), TCF/LEF activation (B), STAT3
Tyr705 phosphorylation (C), and IL-6 secretion (D) were determined in U251 glioblastoma cell lines. Receptor expression was induced upon doxycycline (Dox)
stimulation of the cells. AlF3 was included as a positive control for InsP production. Graphs are representatives of at least three individual experiments
performed in triplicate (A and B) or pooled data of three individual experiments performed in singlicate (C) or duplicate (D). Data are presented as mean  S.D.
(error bars). **, p  0.01; ***, p  0.001; and ****, p  0.0001.
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Despite ongoing debates (47–49), multiple HCMV-encoded
proteins and genes, including US28 (16, 20, 31), have been
detected in glioblastoma tissue samples (18). Moreover, high
expression of HCMV IE1 antigen in glioblastoma is associated
with poor prognosis (19), and adjuvant antiviral therapy (50, 51)
or HCMV-specific immunotherapy (52, 53) showed promising
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improvements in glioblastoma patient survival rates. In the cur-
rent study, expression of another constitutively active HCMV-
encoded GPCR, UL33, promoted a proliferative phenotype in
U251 glioblastoma cells, as observed both in 3D cell culture and
an orthotopic glioblastoma mouse model.
The transcription fingerprint of UL33 in HEK293T cells
accentuated the oncomodulatory signaling properties of this
receptor. Activation of transcription factors STAT3, AP-1,
NFAT, TCF/LEF, SRF, HIF-1, and the VEGF and COX-2 pro-
moters by UL33 is reported here for the first time and further
substantiates UL33’s potential to constitutively drive prolifera-
tive, proangiogenic, and proinflammatory signaling pathways.
The activation of CREB by UL33 is in line with previous reports
in COS-7 (29, 30) and HCMV-infected glioblastoma cells (30).
However, in contrast to our observations in HEK293T cells,
NF-B and SRF were not activated by UL33 in COS-7 cells (29,
54). These findings imply different consequences of UL33
expression in different cell types and potentially in different
tumor types.
In U251 cells, UL33 enhanced TCF/LEF- and STAT3-driven
transcription as well as production of IL-6. Activation of these
pathways is of pathological relevance given their roles in the
biology of glioblastoma and HCMV. In glioma, cytoplasmic and
nuclear expression of -catenin, a transactivator of TCF/LEF, is
positively correlated with tumor grade and negatively corre-
lated with patient survival (55, 56). Knockdown of -catenin
inhibits proliferation of U251 and U87 glioblastoma cells in
vitro as well as U251 tumor growth in a xenograft mouse model
(55, 57). Moreover, activation of -catenin and TCF/LEF is
enhanced upon HCMV Titan 2B infection of U373 glioblas-
toma cells (58). Previously, a link among HCMV infection, IL-6
production, STAT3 Tyr705 phosphorylation, and prognosis was
reported for glioblastoma patients, including an important role
for US28 (16, 31). Similarly, UL33-mediated activation of the
IL-6/STAT3 axis could be instrumental in the aggravation of
HCMV-associated malignancy.
Based on our data, both UL33 and US28 constitutively acti-
vate oncomodulatory signaling pathways. However, the effect
of UL33 on in vitro and in vivo tumor growth was not as pro-
nounced as for US28. This is likely attributed to differential
signaling by the receptors.
When comparing the signaling repertoire of UL33 with that
of US28, we observed that the employed signaling networks
partly overlap. Both receptors activated STAT3, AP-1, NFAT,
TCF/LEF, HIF-1, and the VEGF and the COX-2 promoters in
HEK293T cells and the IL-6/STAT3 axis in U251 cells. The
latter was also confirmed in a viral setting. In addition, impor-
tant differences in signaling output were observed. Although
constitutively coupling to Gq proteins is essential for the foci-
forming capacity of both receptors in NIH-3T3 cells, InsP pro-
duction, a common consequence of Gq activity, was only stim-
ulated by US28 in HEK293T and U251 cells. This suggests
differences upstream in the signaling pathways activated by the
receptors at the level of Gq proteins or effector enzymes. In
addition, the magnitude of TCF/LEF and STAT3 activation in
U251 cells and activation of CREB and SRF in HEK293T cells
Figure 4. UL33 is expressed and induces STAT3 activation in HCMV-infected U251 cells. U251 cells were infected with HCMV Merlin UL33-HA virus. A,
every 24 h, over a time frame of 9 days, the expression of IE1 (blue), UL33 (anti-HA staining; green), and US28 (polyclonal anti-US28 antibodies; red) was
monitored. B and D, 6 dpi the localization of UL33 (anti-HA staining) was compared with US28 (polyclonal anti-US28 antibodies). Arrows indicate examples of
cells with high UL33 and low US28 abundance or vice versa. C, costaining of UL33 (anti-HA antibody) and US28 (polyclonal anti-US28 antibodies) with HCMV
pp28 at 6 dpi. Arrows indicate examples of cells with a perinuclear VAC. E and F, STAT3 activity in U251–3SFP cells upon infection with WT (UL33-HA),
UL33-deficient (UL33), or US28-deficient (UL33-HA, US28) Merlin virus as determined 5 dpi. Graphs are representatives of two (F) and three (E) individual
experiments performed in triplicate. Data are depicted as mean  S.D. (error bars). ***, p  0.001; and ****, p  0.0001. UI, uninfected; RLU, relative light units.
Figure 5. UL33 promotes tumorigenesis in U251 malignant glioma cells. A, U251 iUL33 and U251 iUS28 cells were cultured as 3D spheroids, and the effect
of receptor expression was assessed. The graph depicts pooled data of three individual experiments performed in octuplicate, presented as mean  S.D. (error
bars). B, orthotopic glioblastoma model in which U251-FM iUL33, U251-FM iUS28, or U251-FM cells were injected in the striatum of mice. Mice were fed
doxycycline in their drinking water to induce UL33 and US28 expression. Tumor size was measured via bioluminescence imaging (BLI) in six mice per cell line.
Data are depicted as mean  S.E. (error bars). C, survival of mice in the in vivo study. *, p  0.05; **, p  0.01; and ****, p  0.0001.
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differed between UL33 and US28. The dissimilitude in activa-
tion of STAT3 given similar excretion of IL-6 suggest that addi-
tional factors, besides IL-6, contribute to US28-mediated
STAT3 activation in U251 cells. Also, NF-B activation was
only marginally enhanced in UL33-expressing cells where
NF-B is a key hub in US28-mediated signaling (4, 31). Remark-
ably, factors known to be regulated by NF-B in the context of
US28 signaling such as COX-2, IL-6, and STAT3 (5, 31) were
up-regulated with similar efficacy by UL33 and US28. It would
be of interest to study the difference in activation mechanism
for these factors in further detail.
Upon infection with HCMV, we observed spatiotemporal
differences in the expression of UL33 and US28 in glioblastoma
cells. US28 is expressed early after infection, whereas both
receptors were detected at later stages of HCMV infection.
Coexpression of UL33 and US28 in infected cells might affect
their reciprocal signaling characteristics by formation of
UL33–US28 heteromers or via cross-talk at the level of signal-
ing (59). In agreement with previous observations, both recep-
tors localized mainly in the virion assembly compartment (43,
44). Nevertheless, direct comparison of UL33 and US28 in
infected U251 cells showed differences in localization with
UL33 less strictly localized to the perinuclear VAC. This differ-
ence in subcellular localization suggests that the receptors
might engage different signaling pools. Additionally, the
marked differences observed between UL33 and US28 expres-
sion levels in individual cells imply regulation of viral gene
expression by host cell factors. Further studies are required to
identify which cellular factors and/or differentiation state of
tumor cells dictates the expression of UL33 and US28.
Although it would be interesting to study UL33 in viral con-
text in vivo, such experiments are complicated by HCMV’s
strict species tropism. Nonetheless, mouse and rat CMVs are
well characterized in vivo and encode homologs of UL33 (37–
41). Furthermore, recombinant MCMV has been used as an in
vivo model to study HCMV-encoded GPCR function (39, 40,
60). When translating findings obtained in these model systems
to HCMV pathology, it is important to understand the func-
tional similarities and differences between UL33 and its CMV
homologs. With respect to the activation of CREB, NFAT, and
NF-B, UL33 signaling overlapped with that of MCMV M33
(29, 39). UL33 signaling also corresponded to NF-B and SRF
activation by RCMV R33 (61). UL33, like M33 (29) and R33
(61), was previously shown to induce the accumulation of InsP
in COS-7 cells (29, 30). At best, we observed minimal elevation
of InsP levels by UL33 in HEK293T or U251 cells, highlighting
the significance of the cellular background. Besides, functional
differences between UL33 homologs also exist. For example,
CREB is activated by UL33 and inhibited by R33 (61). Taken
together, UL33 signaling displays similarities, but also clear dif-
ferences, with that of M33 and R33. This might be of particular
importance when using MCMV and RCMV as model systems
to study the function of UL33 in a viral context.
Besides US28 and UL33, also EBV- and KSHV-encoded
GPCRs BILF1 (7) and ORF74 (8) play important roles in the
pathogenesis of herpesvirus-associated malignancies. Hence,
based on our data, UL33 appears to be the fourth herpesvirus-
encoded GPCR with intrinsic oncogenic properties. These
receptors share the capacity to activate proangiogenic, prolifer-
ative, and proinflammatory signaling pathways in a ligand-
independent manner and thereby stimulate tumorigenicity.
Thus, rewiring of cellular signaling through the expression
of constitutively active GPCRs might be a common mecha-
nism by which Herpesviridae members promote oncogene-
sis. This corresponds well with the transforming potential of
constitutively active G protein mutants and the high occur-
rence of activating mutations in GPCRs and G proteins in
human tumors (62).
In conclusion, the HCMV-encoded GPCR UL33 is able to
exert oncomodulatory activity via the induction of prolifera-
tive, proinflammatory, and proangiogenic pathways. The dif-
ferences in expression and functional characteristics of UL33
and US28 might suggest that HCMV has devised distinct means
to control (host) cellular functions through the expression of
different viral GPCRs. These insights improve our understand-
ing of HCMV’s ability to aggravate tumor progression in
HCMV-associated malignancies.
Experimental procedures
Cell lines and cell culture
NIH-3T3 cells (ATCC, Manassas, VA) stably transfected
with UL33-eGFP (AD169 strain) were generated and cultured
as described previously for mock NIH-3T3 and NIH-3T3-US28
(VHL/E strain) cells (6). The U251 cell line was authenticated
by short tandem repeat profiling (Baseclear B.V., Leiden, The
Netherlands). U251 cell lines with inducible expression of (HA-)
US28 (VHL/E strain) or UL33(-HA) (AD169 strain) and/or
constitutive FM expression were generated by lentiviral trans-
duction (20, 32). Linear dsDNA encoding STAT3 transcription
recognition elements flanked by AscI and PstI cloning sites was
obtained by single-cycle PCR using oligonucleotides A and B
(Table 1). Lentiviral STAT3 firefly luciferase reporter gene plas-
mids (3SFP) were constructed by subcloning three STAT3
transcription recognition elements in the backbone of the len-
tiviral 7TFP reporter plasmid (63) using the above-mentioned
cloning sites. To introduce the 7TFP and 3SFP reporters in
U251-iHA-US28, U251-iUL33-HA, or U251 cells, lentiviruses
were produced upon transfection of HEK293T cells with pack-
aging vectors pMD2.G and psPAX2 (a gift from Didier Trono
(Addgene plasmid 12260)) and 7TFP or 3SFP plasmids. The
U251 cell lines were cultured as described previously (32), and
receptor expression was induced using 1 g/ml doxycycline
(D9891, Sigma-Aldrich). HEK293T and HFFF TR cells (kindly
provided by Dr. Richard J. Stanton) were cultured as described
previously (20, 42).
HCMV Merlin BAC recombineering
SW102 Escherichia coli carrying the HCMV Merlin BAC
pAL1502, a variant of BAC pAL1498 (42) lacking the eGFP
Table 1
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tag, were acquired from Dr. Richard J. Stanton. Recombineer-
ing was performed using galK-positive/negative selection as
described previously by Warming et al. (64). Adaptations to
the protocol used to generate the HCMV Merlin BAC
recombinants are specified below. The galK expression cas-
sette was amplified from pgalK (Fredrick National Labora-
tory for Cancer Research) by PCR using oligonucleotide
primers with homology arms targeting specific regions in the
Merlin BACs (Table 2). Primers 1– 4 were used to replace
US28 and UL33 with galK, whereas introduction of galK in
front of the stop codon of UL33 using primers 5 and 6
allowed epitope tagging of UL33. To remove galK and gen-
erate US28, UL33, and UL33-HA BACs, dsDNA was gen-
erated by PCR using Pfu polymerase and oligonucleotides
7–12 (Table 2). The following PCR conditions were used:
94 °C for 15 s, 30 s at 57 °C for US28/54 °C for UL33/60 °C
for UL33-HA, 68 °C for 60 s, two cycles.
BAC isolation and verification
BAC DNA was isolated using a NucleoBond Xtra BAC kit
(Machery Nagel, Düren, Germany). Recombinants were com-
pared with pAL1502 after BamHI and HindIII digestion. The
US28 and UL33 gene regions were sequenced (Eurofins
Genomics, Ebersberg, Germany) upon PCR amplification using
primers 13–22 (Table 2) and the following conditions: 94 °C for
30 s, 55 °C for 30 s, 72 °C for 3 min, 30 cycles.
Virus production
HFFF TR cells were transfected with BAC DNA (2 g/2 
106 cells) using the Amaxa basic fibroblast Nucleofector kit
(Lonza, Basel, Switzerland) and an Amaxa Nucleofector
(Lonza). Subsequent virus productions were initiated by infec-
tion of HFFF TR cells at m.o.i. 0.02. Of note, expression of RL13
and the UL128 locus was repressed during virus production in
HFFF TR cells. IE1 staining in HFFF TR cells 3 dpi was used to
determine virus titers.
Transfection
Transient transfections of HEK293T cells were performed
using the polyethylenimine method (65). One day after plating,
HEK293T cells were transfected with increasing amounts (0.4 –
120 ng) of pcDEF3-UL33-HA (AD169 strain) or pcDEF3-
US28-HA (VHL/E strain) supplemented with empty pcDEF3
vector to a total of 2 g of DNA/1  106 cells. For reporter gene
assays, 1 g of reporter gene plasmid was cotransfected.
Receptor ELISA
24 h post-transfection of HEK293T cells and 48 h post-recep-
tor induction in the U251 cell lines, the cells were fixed and
permeabilized. Expression of HA-tagged receptors was deter-
mined using anti-HA antibody (11867423001, Sigma-Aldrich)
and anti-rat horseradish peroxidase– conjugated antibody
(31470, Thermo Fisher Scientific, Waltham, MA). Absorbance
was measured at 490 nm using a PowerWave X340 (BioTek,
Winooski, VT).
Immunofluorescence microscopy
Stably transfected NIH-3T3 cells and U251 cell lines were
fixed 1 day postseeding and -receptor induction. After permea-
bilization, UL33 and US28 expression was visualized using rab-
bit anti-UL33 (22) or rabbit anti-US28 antibodies (generated
by Covance, Princeton, NJ (36)) and Alexa Fluor 546 –
conjugated anti-rabbit (A11010, Thermo Fisher Scientific) or
Alexa Fluor 488 – conjugated anti-rabbit antibodies (A11008,
Thermo Fisher Scientific), respectively. U251 cells were
infected with HCMV Merlin at m.o.i. 3, and cells were fixed for
immunofluorescence analysis every 24 h over a time course of 9
days. In Merlin-infected U251 cells, UL33 was stained using rat
anti-HA and Alexa Fluor 488 –linked anti-rat antibodies
(A11006, Thermo Fisher Scientific). Visualization of US28 was
performed as in NIH-3T3 cells. Mouse anti-immediate early
antigen (MAB810R, Merck Millipore, Billerica, MA) and Alexa
Fluor 350 – conjugated anti-mouse (A11045, Thermo Fisher
Table 2
Primers used for BAC recombineering and sequencing
Primers 1– 6 were used to introduce galK (homology arm is italicized and sequence recognizing galK is underlined), and primers 7–12 were used to remove galK (homology
arm is italicized, complementary sequence is underlined, and glycine  HA tag is bold). The deletion of galK, US28, or UL33 was confirmed using primers 13–18. Primers
16 and 18 –22 were employed for sequencing of the recombineering products. The oligonucleotides were purchased from Eurofins Genomics.
Code Name Sequence
1 US28-	galK F 5-GTGCGTGGACCAGACGGCGTCCATGCACCGAGGGCAGAACTGGTGCTATCCCTGTTGACAATTAATCATCGGCA-3
2 US28-	galK R 5-ATCCATAACTTCGTATAATGTATGCTATACGAAGTTATAGCGCTTTTTTATCAGCACTGTCCTGCTCCTT-3
3 Ul33-	galK F 5-CGGAAGCGTCGTCGCCCCGGACTGCGCCCGCGGTCTGCTATTCGTCCACGCCTGTTGACAATTAATCATCGGCA-3
4 Ul33-	galK R 5-GGGAAATGGCGACGGGTTCTGGTGCTTTCTGAATAAAGTAACAGGAAAGCTCAGCACTGTCCTGCTCCTT-3
5 UL33galK F 5-CAAAAATCCCCCATCGACTCTCACAATCGCATCATAACCTCAGCGGGGTACCTGTTGACAATTAATCATCGGCA-3
6 UL33galK R 5-AAATGGCGACGGGTTCTGGTGCTTTCTGAATAAAGTAACAGGAAAGCTCATCAGCACTGTCCTGCTCCTT-3
7 galK-	US28 F 5-CAGTCTCTCGGTGCGTGGACCAGACGGCGTCCATGCACCGAGGGCAGAACTGGTGCTATCTAAAAAAGCG-3
8 galK-	US28 R 5-TTAATTAAGGATCCATAACTTCGTATAATGTATGCTATACGAAGTTATAGCGCTTTTTTAGATAGCACCA-3
9 galK-	Ul33 F 5-CTCCAGAACCCGGAAGCGTCGTCGCCCCGGACTGCGCCCGCGGTCTGCTATTCGTCCACGGCTTTCCTGT-3
10 galK-	Ul33 R 5-CGTATATGAGGGGAAATGGCGACGGGTTCTGGTGCTTTCTGAATAAAGTAACAGGAAAGCCGTGGACGAA-3
11 UL33galK-	UL33HA F 5-CAAAAATCCCCCATCGACTCTCACAATCGCATCATAACCTCAGCGGGGTAGGCTACCCGTACGACGTCCCAGACTACGCC-3
12 UL33galK-	UL33HA R 5-AAATGGCGACGGGTTCTGGTGCTTTCTGAATAAAGTAACAGGAAAGCTCAGGCGTAGTCTGGGACGTCGTACGGGTAGCC-3
13 galK internal F 5-CTCTGTTTGCCAACGCATTTGG-3
14 galK internal R 5-CGAAATCATCGCGCATAGAGG-3
15 US28 internal F 5-CGCATTTCCAGAATCGTTGC-3
16 Downstream US28 R 5-CCCTGAACATGTCCATCAGG-3
17 UL33 internal F 5-GCGTGTTACTCATCTCCTTCG-3
18 Downstream UL33 R 5-GGACGTCGTTTTTATCGTACCG-3
19 Upstream US28 F 5-GTAATTCGATCCTCTCTCACGC-3
20 Downstream US28 R 5-CTTTGCATACTTCTGCCTGC-3
21 Upstream UL33 F 5-CGCCGCATTTTTTCAGGATCTTGG-3
22 Downstream UL33 R 5-CGGTACGATAAAAACGACGTCC-3
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Scientific) antibodies were used to determine IE1 expression in
infected U251 and HFFF TR cells. Epifluorescence imaging was
performed using a Nikon TE200 microscope (Nikon, Tokyo,
Japan).
For imaging at a higher resolution, confocal microscopy
was performed on Merlin-infected U251 cells fixed at 5 dpi
(m.o.i. 6). UL33 and US28 were stained using rat anti-HA
and rabbit anti-US28 antibodies, respectively, as described
above. pp28 was detected using mouse anti-pp28 (sc-69749,
Santa Cruz Biotechnology). Cell nuclei were stained using
DAPI (D9542, Sigma-Aldrich). Confocal laser-scanning
microscopy was performed at room temperature on a Nikon
A1R microscope (Nikon) equipped with a 60  1.4 oil-
immersion objective. Samples were irradiated using the
405-, 488-, and 561-nm laser lines with 2, 0.5, and 1%, respec-
tively. The 488 and 561 channels were detected with GaAsP
photomultiplier tubes. The 405 channel (DAPI) was detected
with a regular photomultiplier tube. The samples were
scanned with a Nikon Galvano scanner at 2048  2048 pix-
els, corresponding to 51.5-nm pixel size. NIS-Elements AR
4.60.00 software (Nikon) was used for image acquisition. Fiji
software was used for image analysis (66).
Western blotting
U251 cells were grown in serum-free conditions before
lysis in native lysis buffer (32) 48 h post-receptor expression.
A standard procedure was used for Western blot analysis.
Membranes were probed with rabbit anti-STAT3 (4904, Cell
Signaling Technology), rabbit anti-phospho-STAT3 (Tyr705)
(9145, Cell Signaling Technology), and mouse anti--actin
(A5316, Sigma-Aldrich) antibodies followed by horseradish
peroxidase– conjugated secondary antibodies (170-6515 or
170-6516, Bio-Rad). Proteins were visualized using ECL sub-
strate (NEL104001EA, PerkinElmer Life Sciences) and
imaged using a ChemiDoc imager (Bio-Rad). Protein abun-
dance was quantified using Image Studio software (LI-COR
Biosciences, Lincoln, NE) and normalized to -actin loading
control.
Foci and spheroid formation
The formation of foci in NIH-3T3 cells and spheroid growth
in U251 cells were evaluated as described before (20) with
exception of Gq inhibition. Treatment with Gq inhibitor
YM-254890 (300 nM) or DMSO vehicle was initiated 6 h after
cell seeding, and treatment medium was refreshed every 3 days.
Foci were quantified using Fiji software.
Reporter gene assays
Luciferase activity was measured 48 h after induction of
receptor expression in U251 cell lines, under serum-free condi-
tions, or 24 h post-transfection of HEK293T cells. U251–3SFP
cells were infected with HCMV Merlin WT (UL33-HA), UL33-
knockout (UL33), or US28-knockout (UL33-HA, US28)
virus at similar infection rates. Five dpi, after 2 days of serum
starvation, luciferase activity was quantified. Similarly, lucifer-
ase activity was evaluated in U251–3SFP and U251-FM cells
upon parallel infection at m.o.i. 6, which functioned as an exter-
nal control for the STAT3 activation in infected U251 cells.
Bioluminescence was measured using a Victor3 plate reader
(PerkinElmer Life Sciences).
Inositol phosphate accumulation
HEK293T and U251 cells were labeled overnight in inositol-
free medium supplemented with 1 Ci/ml myo[2-3H]inositol
(PerkinElmer Life Sciences). One day post-transfection or -re-
ceptor induction, [3H]inositol phosphates were quantified (31).
IL-6 ELISA
Conditioned medium, accumulated from 24 to 48 h post-
receptor induction, was collected from serum-starved U251
cell lines. IL-6 concentrations were measured using a human
IL-6 Quantikine kit (R&D Systems, Minneapolis, MN).
Quantitative real-time PCR
U251, U251-FM-iUL33, and U251-FM-iUS28 cells were syn-
chronized in serum-free growth medium supplemented with
doxycycline. Culture medium was refreshed after 1 day, and
another 24 h later cellular RNA was extracted using TRIzol
reagent. mRNA was converted into cDNA through reverse
transcription using the iScript cDNA Synthesis kit (Bio-Rad)
according to the manufacturer’s instructions. PCRs were per-
formed using LC SYBR Green Master I reagent (Roche Applied
Science) and the LightCycler 480 PCR detection system (Roche
Applied Science) at 95 °C for 10 min followed by 45 cycles of
95 °C for 10 s, 60 °C for 15 s, and 70 °C for 15 s. UL33 and US28
transcripts were quantified using primers targeting the identi-
cal 3-UTR of their mRNA: F, CCGCGGTTCGAAGGTAAG,
R, CGATCATTACTAACCGGTACGC. ACTB was used as ref-
erence gene: F, TCCACCTTCCAGCAGATGTG; R, GCATT-
TGCGGTGGACGAT. Receptor mRNA abundance was calcu-
lated using the 2
Ct method and ACTB as an internal
control.
Animal studies
For the xenograft model (6), stably transfected NIH-3T3 cells
were injected subcutaneously into the flank of 8 –10-week-old
female athymic nude mice (Harlan/Envigo, Horst, The Nether-
lands). For the orthotopic glioblastoma model, U251 cells were
stereotactically injected in the striatum of 6-week-old female
athymic nude mice (Harlan/Envigo) as described previously
(20).
Ethics statement
Animal experiments were conducted in compliance with
Dutch law and European Community Council Directive 2010/
63/EU for laboratory animal care and approved by the VU Med-
ical Center animal experimentation commission (license num-
ber NCH13-03).
Data analysis
Student’s t test (two-tailed, significance level of   0.05,
using Holm–Šídák method) or analysis of variance with multi-
ple comparisons test (Dunnett correction) was performed
using Prism software (GraphPad, San Diego, CA).
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